Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02110563 |
| Title | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Dicerna Pharmaceuticals, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Stanford Cancer Institute | Stanford | California | 94305 | United States | Details | |
| University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| South Texas Accelerated Research Therapeutics (START)-Midwest | Grand Rapids | Michigan | 49503 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| South Texas Accelerated Research Therapeutics (START), LLC | San Antonio | Texas | 78229 | United States | Details |